Pharmacokinetics of intravenous and transdermal fentanyl in alpacas. 2017

M Lovasz, and T K Aarnes, and J A E Hubbell, and R M Bednarski, and P Lerche, and J Lakritz
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, USA.

The purpose of the study was to determine pharmacokinetics of fentanyl after intravenous (i.v.) and transdermal (t.d.) administration to six adult alpacas. Fentanyl was administered i.v. (2 μg/kg) or t.d. (nominal dose: 2 μg kg-1  hr-1 ). Plasma concentrations were determined using liquid chromatography-mass spectrometry. Heart rate and respiratory rate were assessed. Extrapolated, zero-time plasma fentanyl concentrations were 6.0 ng/ml (1.7-14.6 ng/ml) after i.v. administration, total plasma clearance was 1.10 L hr-1  kg-1 (0.75-1.40 L hr-1  kg-1 ), volumes of distribution were 0.30 L/kg (0.10-0.99 L/kg), 1.10 L/kg (0.70-2.96 L/kg) and 1.5 L/kg (0.8-3.5 L/kg) for V1 , V2 , and Vss , respectively. Elimination half-life was 1.2 hr (0.5-4.3 hr). Mean residence time (range) after i.v. dosing was 1.30 hr (0.65-4.00 hr). After t.d. fentanyl administration, maximum plasma fentanyl concentration was 1.20 ng/ml (0.72-3.00 ng/ml), which occurred at 25 hr (8-48 hr) after patch placement. The area under the plasma fentanyl concentration-vs-time curve (extrapolated to infinity) after t.d. fentanyl was 61 ng*hr/ml (49-93 ng*hr/ml). The dose-normalized bioavailability of fentanyl from t.d. fentanyl in alpacas was 35.5% (27-64%). Fentanyl absorption from the t.d. fentanyl patch into the central compartment occurred at a rate of approximately 50 μg/hr (29-81 μg/hr) between 8 and 72 hr after patch placement.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008297 Male Males
D002161 Camelids, New World Camelidae of the Americas. The extant species are those originating from South America and include alpacas, llamas, guanicos, and vicunas. Alpacas,Guanacos,Llamas,Lama glama,Lama glama guanicoe,Lama guanicoe,Lama pacos,Vicugna pacos,Vicugna vicugna,Vicunas,Alpaca,Camelid, New World,Guanaco,Llama,New World Camelid,New World Camelids,Vicuna
D005260 Female Females
D005283 Fentanyl A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078) Phentanyl,Duragesic,Durogesic,Fentanest,Fentanyl Citrate,Fentora,R-4263,Sublimaze,Transmucosal Oral Fentanyl Citrate,R 4263,R4263
D000701 Analgesics, Opioid Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. Opioid,Opioid Analgesic,Opioid Analgesics,Opioids,Full Opioid Agonists,Opioid Full Agonists,Opioid Mixed Agonist-Antagonists,Opioid Partial Agonists,Partial Opioid Agonists,Agonist-Antagonists, Opioid Mixed,Agonists, Full Opioid,Agonists, Opioid Full,Agonists, Opioid Partial,Agonists, Partial Opioid,Analgesic, Opioid,Full Agonists, Opioid,Mixed Agonist-Antagonists, Opioid,Opioid Agonists, Full,Opioid Agonists, Partial,Opioid Mixed Agonist Antagonists,Partial Agonists, Opioid
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

M Lovasz, and T K Aarnes, and J A E Hubbell, and R M Bednarski, and P Lerche, and J Lakritz
September 2019, Journal of veterinary pharmacology and therapeutics,
M Lovasz, and T K Aarnes, and J A E Hubbell, and R M Bednarski, and P Lerche, and J Lakritz
July 2003, Equine veterinary journal,
M Lovasz, and T K Aarnes, and J A E Hubbell, and R M Bednarski, and P Lerche, and J Lakritz
August 1999, American journal of veterinary research,
M Lovasz, and T K Aarnes, and J A E Hubbell, and R M Bednarski, and P Lerche, and J Lakritz
September 2002, Anesthesia and analgesia,
M Lovasz, and T K Aarnes, and J A E Hubbell, and R M Bednarski, and P Lerche, and J Lakritz
June 2000, American journal of veterinary research,
M Lovasz, and T K Aarnes, and J A E Hubbell, and R M Bednarski, and P Lerche, and J Lakritz
September 2015, Basic & clinical pharmacology & toxicology,
M Lovasz, and T K Aarnes, and J A E Hubbell, and R M Bednarski, and P Lerche, and J Lakritz
August 2015, Journal of veterinary pharmacology and therapeutics,
M Lovasz, and T K Aarnes, and J A E Hubbell, and R M Bednarski, and P Lerche, and J Lakritz
January 2000, Clinical pharmacokinetics,
M Lovasz, and T K Aarnes, and J A E Hubbell, and R M Bednarski, and P Lerche, and J Lakritz
November 2002, The Medical journal of Australia,
M Lovasz, and T K Aarnes, and J A E Hubbell, and R M Bednarski, and P Lerche, and J Lakritz
January 1989, Pharmacotherapy,
Copied contents to your clipboard!